Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor

Nature Medicine

Volumn 8, Issue 2, 2002, Pages 128-135

  Guba, Markus ^a   Von Breitenbuch, Philipp ^a   Steinbauer, Markus ^a   Koehl, Gudrun ^a   Flegel, Stefanie ^a   Hornung, Matthias ^a   Bruns, Christiane J ^a   Zuelke, Carl ^a   Farkas, Stefan ^a   Anthuber, Matthias ^a   Jauch, Karl Walter ^a   Geissler, Edward K ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER RECURRENCE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; HIGH RISK PATIENT; HISTOPATHOLOGY; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKINFOLD; TUMOR GROWTH;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ENDOTHELIAL GROWTH FACTORS; LYMPHOKINES; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ANIMALIA;

EID: 0036174289     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0202-128     Document Type: Article

References (41)

1. Recurrence of bronchioloalveolar carcinoma in transplanted lungs
2. Liver transplantation for cholangiocarcinoma: Results in 207 patients
3. Occurrence of cancers in immunosuppressed organ transplant recipients
4. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin
5. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression
6. Mechanism of action of rapamycin: New insights into the regulation of G1-phase progression in eukaryotic cells
7. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study
8. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
9. The mechanism of action of cyclosporin A and FK506
10. The incidence of tumours in renal transplant recipients with long-term immunosuppressive therapy
11. Modulation of hypoxia-inducible factor 1 α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics
12. 2 homeostasis by hypoxia-inducible factor 1
13. Synergistic cooperation between hypoxia and transforming growth factor-β pathways on human vascular endothelial growth factor gene expression
14. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis
15. Mechanisms of coronary angiogenesis in response to stretch: Role of VEGF and TGF-β
16. Angiogenesis in cancer and other diseases
17. A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis
18. Activity of rapamycin (AY-22,989) against transplanted tumors
19. Quantitative analysis of microvascular structure and function in the amelanotic melanoma A-Mel-3
20. Effect of host microenvironment on the microcirculation of human colon adenocarcinoma
21. Tumor induction of VEGF promoter activity in stromal cells
22. The role of vascular endothelial growth factor in pathological angiogenesis
23. p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation
24. MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor
25. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis
26. Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation
27. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
28. Angiogenesis research: Guidelines for translation to clinical application
29. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
30. Tumor-host interactions in the gallbladder suppress distal angiogenesis and tumor growth: Involvement of transforming growth factor β 1
31. Antiangiogenesis by cyclosporine
32. Corneal neovascularization induced by xenografts or chemical cautery. Inhibition by cyclosporin A
33. Cyclosporine induces cancer progression by a cell-autonomous mechanism
34. Establishment of mouse colonic carcinoma cell lines with different metastatic properties
35. Rapamycin in transplantation: A review of the evidence
36. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy
37. Differential effects of short-term ACE- and AT1-receptor inhibition on postischemic injury and leukocyte adherence in vivo and in vitro
38. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases
39. The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion
40. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: Effect on in vivo mammary tumor growth and angiogenesis
41. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR